14. Oncología - Sociedad Española de Farmacia Hospitalaria

More documents

Recommendations

Info

1222 FARMACIA HOSPITALARIAatment. Special Issue: 24th Annual San AntonioBreast Cancer Symposium. 2001; 69:210. Abstract8.53. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifenfor prevention of breast cancer: report ofthe National Surgical Adjuvant Breast and BowelProject P-1 Study. J Natl Cancer Inst 1998 Sep 16;90(18):1371-8854. Powles T, Eeles R, Ashley S, et al. Interim analysis ofthe incidence of breast cancer in the Royal MarsdenHospital tamoxifen randomised chemopreventiontrial. Lancet 1998 Jul 11; 352(9122):98-101.55. Veronesi U, Maisonneuve P, Costa A, et al. Preventionof breast cancer with tamoxifen: preliminaryfindings from the Italian randomised trial amonghysterectomised women. Italian Tamoxifen PreventionStudy. Lancet 1998 Jul 11; 352(9122):93-7.56. Gail MH, Brinton LA, Byar DP, et al. Projectingindividualized probabilities of developing breastcancer for white females who are being examinedannually. J Natl Cancer Inst 1989 Dec 20; 81(24):1879-86.57. Bayoumi AM, Brown AD, Garber AM. Cost-effectivenessof androgen suppression therapies inadvanced prostate cancer. J Natl Cancer Inst 2000Nov 1; 92(21):1731-9.58. Crawford J, Ozer H, Stoller, et al. Reduction bygranulocyte colony-stimulating factor of fever andneutropenia induced by chemotherapy in patientswith small-cell lung cancer. N Engl J Med 1991;325: 164-170.59. Fanucchi M, Glaspy J, Crawford J, et al. Effects ofpolyehylene glycol-conjugated recombinant humanmegacaryocite growth and developpmentfactor on platelet counts after chemotherapy forlung cancer. N Eng J Med 1997; 336: 404-409.60. Basser R, Clarke K, Fox R, et al. Randomized double-blindplacebo-controlled phase I trial of pegylatedmegacariocyte growth and developpmentfactor (PEG-rHuMGDF) administered to 10 patientswith advanced cancer before and after chemotherapy:early results. Blood 1995; 86(suppl. 1):257a.61. Cascinu S, Fedeli A, Del Ferroe E, et al. Recombinanthuman erythropoietin treatment in cisplatinassociated anemia: a randomized double-blind trialwith placebo. J Clin Oncol 1994; 12:1058-1062.62. Miller CB, Platanias LC, Mills SR, et al. Phase I-IItrial of erythropoietinin the treatment of cisplatinassociatedanemia. J Nat Cancer Inst 1992; 84:98-103.63. Lucarelli CD. Chemotherapy-induced oral mucositis:causes and treatment. Cancer Chemotherapy Update1984; 2:1-4.64. Pfeiffer JL, Madsen EL, Hansen O, et al. Effect ofprophylactic sucralfate suspension on stomatitis inducedby cancer chemotherapy. A randomized,double-blind cross-over study. Acta Oncol 1990;29:171-173.65. Shenep JL, Kalwinsky D, Hudson Pr, et al. Oralsucralfate in chemotherapy-induced mucositis. JPediatr 1988; 113(4): 758-763.66. Loprinzi CL, Gosh CH, Camoriano J, et al. PhaseIII controlled evaluation of sucralfate to alleviatestomatitis in patients receiving fluorouracil-basedchemotherapy. J Clin Oncol 1997; 15(3):1235-1238.67. Mahood D, Dose A, Loprinzi CL, et al. Inhibitionof fluorouracil induced stomatitis by oral criotherapy.J Clin Oncol 1991; 9:449-452.68. Cascinu S, Fedeli A, Luzi S, et al. Oral cooling (criotherapy),an effective treatment for prevention of5-fluorouracil induced mucositis. Eur J Cancer1994; 30B(4):234-236.69. Rocke L, Loprinzi CL, Lee J, et al. A randomized clinicaltrial of two different durations of oral criotherapypor prevention of 5-fluorouracil relatedstomatitis. Cancer 1993; 72(7): 2234-2238.70. Meloni G, Capria S, Proia A, et al. Ice pops to preventmelphalan-induced stomatitis. The Lancet1996; 347:1691-1692.71. Gutiérrez Ramos R, Ruano Encinar M, HerreroAmbrosio A, et al. Prevención y tratamiento de laslesiones de la mucosa oral secundarias a quimioterapia.Farm Clin 1997; 14(9): 588-598.72. Ahmed T, Engelking C, Szalgya J, et al. Propanthelineprevention of mucositis from etoposide.Bone Marrow Transplant 1993; 12:131-132.73. Oblon DJ, Paul SR, Oblon MB, et al. Propanthelineprotects the oral mucose after high-dose ifosfamide,carboplatin, etoposide and stem cell transplantation.Bone Marrow Transplant 1997;20:961-963.74. Cowen D, Tardieu M, Schubert M, et al. LowenergyHelium-Neon laser in the prevention oforal mucositis in patients undergoing bone marrowtransplant: results of a double blind randomizedtrial. Int J Radiation Oncology Biol Phys
ONCOLOGÍA12231997; 38(4):697-703.75. Barasch A, Peterson DE, Tanzer JM, et al. Helium-Neon laser effects on conditioning induced oralmucositis in bone marrow transplantation patients.Cancer 1995; 76(12): 2550-2556.76. Barret AP. Evaluation of nystatin in the preventionand elimination of oropharyngeal Candida inimmunosuppressed patients. Oral Surg Oral MedOral Phatol 1984; 58:148-151.77. Hann IM, Prentice HG, Corrinhem R, et. al. Ketoconazoleversus nystatin plus amphotericin B forfungal prophylaxis in severely immunocompromisedpatients. Lancet 1982; 1:826-829.78. Solomon C, Arendorf T, Shaikh A, et al. Benzydaminehydrochloride improves oral mucosal healthin the immunocompromised patient. South AfricanMed J 1996; 86(9): 1136-1137.79. Heskett PH, Kris MG, Grumberg SM, et al. Proposalfor Classifying the Acute Emetogenicidad ofCancer Chemotherapy. J Clin Oncol 1997; 15:103-109.80. ASHP Therapeutic Guidelines on the PharmacologicManagement of Nausea and Vomiting inAdult and Pediatric Patients Receiving Chemotherapyor Radiation Therapy or Undergoing Surgery.AmJ Health Syst Pharm. 1999 Apr 15;56(8):729-6481. Heron JF, Goedhals L, Jordaan JP, et al, on behalf ofthe Granisetron Study Group. Oral GranisetronAlone and in Combination with Dexamethasone:A Double-Blind Randomised ComparisonAgainst High-dose Metoclopramide plus Dexamethasonein Prevention of Cisplatin-Inducedemesis. Ann Oncol 1994; 5:579-584.82. García del Muro X, Vadell C, Pérez Manga G, etal. Randomised Double-Blind Study ComparingTropisetron Alone and in Combination with Dexamethasonein the Prevention of Acute and DelayedCisplatin-Induced Emesis. Eur J Cancer1998; 34(1):193-195.83. Hesketh PJ, Harvey WH, Harker WG, et al. ARandomized, Double-Blind Comparison of IntravenousOndansetron Alone and in Combinationwith Intravenous Dexamethasone in the Preventionof High-Dose Cisplatin-Induced Emesis.J Clin Oncol 1994; 12:596-600.84. The Italian Group for Antiemetic Research. Dexamethasone,Granisetron, or both for the Preventionof Nausea and Vomiting During Chemotherapyfor Cancer. N Engl J Med. 1995; 332:1-5.85. Kirchner V, Aapro M, Terrey JP, et al. A DoubleblindCrossover Study Comparing Prophylactic IntravenousGranisetron Alone or in Combinationwith Dexamethasone as Antiemetic Treatment inControlling Nausea and Vomiting Associated withChemotherapy. Eur J Cancer. 1997; 33(10):1605-161086 Italian Group for Antiemetic Research. Persistenceof Efficacy of Three Antiemetic Regimens andPrognostic Factors in Patients Undergoing ModeratelyEmetogenic Chemotherapy. J. Clin Oncol1995; 13:2417-2426.87 Navari R, Gandara D, Hesketh P, et al. ComparativeClinical Trial of Granisetron and Ondansetron inthe Prophylaxis of Cisplatin-Induced Emesis. JClin Oncol 1995; 13:1242-1248.88. Ruff P, Paska W, Goedhals L, et al. Ondansetroncompared with granisetron in the prophylaxis ofcisplatin-induced acute emesis: a multicentre double-blind,randomised, parallel-group study. TheOndansetron and Granisetron Emesis StudyGroup. Oncology 1994 Jan-Feb; 51(1):113-8.89. Mendarte L, Aguas Compaired M, M MartínezBernabé E, et al. Meta-analysis of granisetron versusondansetron: efficacy and safety in the preventionof acute emesis induced by high dose cisplatincontaining schedules. Med Clin (Barc) 2000 Oct14; 115 (12):456-090. Del Giglio A, Soares HP, Caparroz C, et al. Granisetronis equivalent to ondansetron for prophylaxisof chemotherapy-induced nausea and vomiting:results of a meta-analysis of randomized controlledtrials. Cancer 2000 Dec 1; 89(11):2301-8.91. Navari RM, Kaplan HG, Gralla RJ, et al. Efficacyand Safety of Granisetron, a Selective 5-Hydroxytryptamine-3 Receptor Antagonist, in thePrevention of Nausea and Vomiting Induced byHigh-Dose Cisplatin. J Clin Oncol 1994; 12:2204-10.92. Pérez EA, Hesketh P, Sandback J, et al. Comparisonof Single-Dose Oral Ondansetron in the Preventionof Nausea and Vomiting Induced by ModeratelyEmetogenic Chemotherapy: A Multicenter, Double-Blind,Randomized Parallel Study. J Clin Oncol1998; 16:754-76093. ectasides D, Mylonakis A, Varthalitis J, et al. Comparisonof Two Different Doses of Ondansetronplus Dexamethasone in the Prophylaxis of Cispla-
Page 4 and 5: 1174 FARMACIA HOSPITALARIAprolongar
Page 7 and 8: ONCOLOGÍA1177cos antineoplásicos
Page 9 and 10: ONCOLOGÍA1179Tabla 2. Ejemplos de
Page 11 and 12: ONCOLOGÍA1181Tabla 4. Antineoplás
Page 13 and 14: ONCOLOGÍA1183Tabla 5. Característ
Page 15 and 16: ONCOLOGÍA1185otros agentes antitum
Page 17 and 18: ONCOLOGÍA1187Tabla 8. Ensayos clí
Page 19 and 20: ONCOLOGÍA1189Tabla 10. Tipos de ho
Page 21 and 22: ONCOLOGÍA1191Tabla 11. Líneas de
Page 23 and 24: ONCOLOGÍA1193Tabla 12. Ejemplos ha
Page 25 and 26: ONCOLOGÍA1195Tabla 13. Terapias pa
Page 27 and 28: ONCOLOGÍA1197Tabla 14. Ejemplos de
Page 29 and 30: ONCOLOGÍA1199de 40 mcg/kg, mientra
Page 31 and 32: ONCOLOGÍA1201El dimetilsulfóxido,
Page 33 and 34: ONCOLOGÍA1203Medidasiniciales1) Pa
Page 35 and 36: ONCOLOGÍA1205Tabla 16. Ajuste de d
Page 37 and 38: ONCOLOGÍA1207de los citostáticos
Page 39 and 40: ONCOLOGÍA1209Tabla 18. Principales
Page 43 and 44: ONCOLOGÍA1213be calcular la dosis
Page 45 and 46: ONCOLOGÍA1215Tabla 25. Tratamiento
Page 51: ONCOLOGÍA1221logy recommendations
Page 55 and 56: ONCOLOGÍA1225pitalaris. Barcelona:

14. Oncología - Sociedad Española de Farmacia Hospitalaria

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?